10 Pluristem Therapeutics Analyst Ratings, Earnings, Dividends and Insider Trades | $PSTI | NASDAQ:PSTI | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Pluristem Therapeutics Company Profile (NASDAQ:PSTI) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Pluristem Therapeutics (NASDAQ:PSTI) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 2 Buy Rating(s)Consensus Rating:Buy (Score: 3.00)Consensus Price Target: $5.83 (42.45% upside) Analysts' Ratings History for Pluristem Therapeutics (NASDAQ:PSTI) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare2/7/2014Jefferies GroupBoost Price Target$3.00 -> $3.50View 1/21/2014MLV & Co.Boost Price TargetBuy$4.50 -> $6.00View 9/16/2013Maxim GroupUpgradeHold -> Buy$8.00View 6/5/2013Jefferies GroupLower Price TargetHold$3.50 -> $3.00View 6/4/2013Maxim GroupDowngradeBuy -> HoldView 5/31/2013MLV & Co.Initiated CoverageBuy$4.50View 3/18/2013Jefferies GroupInitiated CoverageHold$3.50View 7/25/2012Maxim GroupInitiated CoverageBuy$8.00View 7/24/2012WBB SecuritiesDowngradeSpeculative Buy -> Hold$4.00 -> $3.75View 5/22/2012Needham & CompanyInitiated CoverageBuy$5.00View (Data available from 3/9/2012 forward) Earnings History for Pluristem Therapeutics (NASDAQ:PSTI)No earnings announcements for this company have been tracked by Analyst Ratings Network Dividend History for Pluristem Therapeutics (NASDAQ:PSTI)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Pluristem Therapeutics (NASDAQ:PSTI)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare1/17/2014Israel Ben-YoramDirectorSell35,625$4.51$160,668.75View 1/13/2014Israel Ben-YoramDirectorSell26,453$4.29$113,483.37View 1/13/2014Yaky YanayCFOSell69,850$4.29$299,656.50View 1/9/2014Yaky YanayCFOSell30,150$4.25$128,137.50View 1/8/2014Israel Ben-YoramDirectorSell44,797$4.12$184,563.64View 11/11/2013Nachum RosmanDirectorSell67,244$3.27$219,887.88View 9/12/2013Israel Ben-YoramDirectorSell52,000$3.07$159,640.00View 5/20/2013Israel Ben-YoramDirectorSell45,429$3.03$137,649.87View (Data available from 1/1/2013 forward) About Pluristem Therapeutics Pluristem Therapeutics Inc. (Pluristem) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from human placenta, a non-controversial, non-embryonic, adult stromal cell source. The placental adherent stromal cells (ASCs) are grown in the Company's PluriX three-dimensional (3-D) bioreactor, which imitates the natural microstructure of the body. It is focusing on clinical indication that the route of administration is intramuscular. This route of administration applicable for several different indications, such as Peripheral artery disease (PAD), Critical limb ischemia (CLI), intermittent claudication, neuropathic pain, wound healing and orthopedic injuries. Headlines: (3/7) Pluristem CEO Zami Aberman to Present on Cell & Gene Therapy Panel Discussion at BIO-Europe Spring 2014 (3/6) US FDA Approves Pluristem's Commercial Scale Cell Manufacturing Process (2/20) Pluristem Submits FDA Orphan Drug Application for Preeclampsia (2/18) Pluristem Receives Key 3D Cell Expansion Patent in Australia (2/21) Pluristem Therapeutics Granted New Patent amid Positive Clinical Trial (2/13) Pluristem CEO Zami Aberman to Speak on Panel at 9th Annual Stem Cell Summit on February 18, 2014 (3/6) Pluristem Therapeutics Says FDA Oks Commercial Scale Cell Manufacturing Process (2/11) Medical Key Opinion Leaders in Preeclampsia Join Pluristem's Steering Committee Industry, Sector and Symbol: Sector: Healthcare Industry: N/A Sub-Industry: N/A Exchange: NASDAQ Symbol: PSTI CUSIP: Key Metrics: Previous Close: $4.2350 Day Moving Average: $4.0647200 Day Moving Average: $3.5576 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $264.8MCurrent Quarter EPS Consensus Estimate: $-0.50 EPS Additional Links: View PSTI on Google FinanceView PSTI on Yahoo FinanceView PSTI's Company Profile on ReutersSearch for Pluristem Therapeutics on Google Pluristem Therapeutics (NASDAQ:PSTI) Chart for Sunday, March, 9, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.